The application of unrelated donor bone marrow transplantation is limited by availability of donors, an expensive, time-consuming process of working up donors, and a high incidence of severe side effects arising from donor- recipient immunological incompatibility. Recent studies suggest that use of unrelated cord blood-derived hematopoietic stem cells for human pediatric transplantation is associated with less severe graft-versus-host disease (GVHD) than seen with marrow from adult unrelated donors. However, graft failures have been observed and concern remains that cell doses from cord blood will be inadequate for adult transplantation. In vitro studies have shown greater potential for ex vivo expansion and gene transduction of cord blood hematopoietic progenitors than with adult marrow or peripheral blood and suggest that cord blood is a superior product for such manipulation. The in vivo application of these observations will be tested in a well characterized large animal model. In vitro characteristics of canine cord blood cells will be compared to those of human cells including colony forming activities, cell surface phenotypes and cell cycle characteristics. Studies will then evaluate and optimize conditions for in vitro expansion of cord blood cells. The hypothesis that cord blood transplants will engraft from subtherapeutic cell doses after ex vivo manipulation and engraft across major immunologic barriers with reduced GVHD will be tested in transplants of histocompatible siblings and mismatched unrelated dogs. The hypothesis that cord blood stem cells can be more readily transduced with retroviral constructs for gene therapy than adult stem cells will be tested by in vitro colony assays and by transplantation studies in conjunction with Project 7. The proposed studies should help define whether ex vivo expansion of cord blood can enhance engraftment after allogeneic transplantation and help determine whether cord blood transplantation for adults can safely supplant the use of marrow from adult unrelated donors.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL036444-19
Application #
6202264
Study Section
Project Start
1999-08-01
Project End
2000-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
19
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Thakar, M S; Bonfim, C; Walters, M C et al. (2017) Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia. Bone Marrow Transplant 52:570-573
Burroughs, Lauri M; Shimamura, Akiko; Talano, Julie-An et al. (2017) Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. Biol Blood Marrow Transplant 23:1669-1677
Vaughn, J E; Anwer, F; Deeg, H J (2016) Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom? Vox Sang 110:5-11
Aki, S Z; Inamoto, Y; Carpenter, P A et al. (2016) Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity. Bone Marrow Transplant 51:1350-1353
Khera, Nandita; Gooley, Ted; Flowers, Mary E D et al. (2016) Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22:1319-1323
Karoopongse, Ekapun; Marcondes, A Mario; Yeung, Cecilia et al. (2016) Disruption of Iron Regulation after Radiation and Donor Cell Infusion. Biol Blood Marrow Transplant 22:1173-1181
Hoffmeister, P A; Storer, B E; Syrjala, K L et al. (2016) Physician-diagnosed depression and suicides in pediatric hematopoietic cell transplant survivors with up to 40 years of follow-up. Bone Marrow Transplant 51:153-6
Gallo, S; Woolfrey, A E; Burroughs, L M et al. (2016) Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? Bone Marrow Transplant 51:1573-1578
Festuccia, Moreno; Deeg, H Joachim; Gooley, Theodore A et al. (2016) Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22:1227-1233

Showing the most recent 10 out of 788 publications